Despite current standard of care therapies for myocardial infarction, significant short- and long-term mortality persists, highlighting the need for new therapies to reduce post-MI left ventricular remodeling.
Answers are grounded in this paper and cite their sources.
Persistent post-MI mortality signals ongoing clinical challenge; leaves open whether novel remodeling therapies can improve survival.
Current therapies for myocardial infarction are geared to try to limit ischemic/reperfusion injury by early and complete reperfusion, including percutaneous coronary interventions, antiplatelet agents, and anticoagulants; and attempts to limit post infarction left ventricular remodeling by inhibitors of the renin-angiotensin-aldosterone pathway or administration of beta blockers. Despite wide use of these therapies, 30-day mortality still runs 7-8% and one year mortality runs around 23% (1).
No takes yet. Share an insight, caveat, or question.
Kloner et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: